Douglass Winthrop Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.4M Buy
61,088
+8,213
+16% +$1.77M 0.27% 45
2026
Q1
$11.5M Buy
52,875
+182
+0.3% +$40.4K 0.21% 47
2025
Q4
$12M Buy
52,693
+1,725
+3% +$393K 0.21% 49
2025
Q3
$11.8M Buy
50,968
+9,022
+22% +$1.84M 0.21% 47
2025
Q2
$7.79M Hold
41,946
0.14% 59
2025
Q1
$8.79M Sell
41,946
-272
-0.6% -$52.9K 0.17% 50
2024
Q4
$7.5M Sell
42,218
-420
-1% -$77.2K 0.15% 58
2024
Q3
$8.42M Buy
42,638
+1,274
+3% +$238K 0.16% 55
2024
Q2
$7.09M Sell
41,364
-801
-2% -$133K 0.14% 62
2024
Q1
$7.68M Buy
42,165
+1,043
+3% +$180K 0.16% 59
2023
Q4
$6.37M Buy
41,122
+437
+1% +$63.7K 0.14% 62
2023
Q3
$6.06M Buy
40,685
+822
+2% +$121K 0.15% 60
2023
Q2
$5.37M Sell
39,863
-480
-1% -$70.4K 0.13% 64
2023
Q1
$6.43M Sell
40,343
-2,026
-5% -$310K 0.17% 56
2022
Q4
$6.85M Sell
42,369
-298
-0.7% -$45.7K 0.19% 51
2022
Q3
$5.73M Sell
42,667
-750
-2% -$108K 0.17% 53
2022
Q2
$6.65M Buy
43,417
+1,163
+3% +$178K 0.19% 49
2022
Q1
$6.85M Sell
42,254
-2,254
-5% -$327K 0.16% 52
2021
Q4
$6.03M Sell
44,508
-600
-1% -$70.9K 0.14% 63
2021
Q3
$4.87M Sell
45,108
-1,925
-4% -$220K 0.12% 68
2021
Q2
$5.3M Sell
47,033
-256
-0.5% -$28.8K 0.13% 62
2021
Q1
$5.12M Buy
47,289
+7,028
+17% +$752K 0.14% 58
2020
Q4
$4.31M Sell
40,261
-200
-0.5% -$19.2K 0.12% 60
2020
Q3
$3.54M Sell
40,461
-2,147
-5% -$202K 0.12% 63
2020
Q2
$4.18M Buy
42,608
+7,914
+23% +$697K 0.16% 57
2020
Q1
$2.64M Sell
34,694
-1,338
-4% -$114K 0.12% 68
2019
Q4
$3.19M Sell
36,032
-3,616
-9% -$300K 0.11% 75
2019
Q3
$3M Sell
39,648
-3,464
-8% -$237K 0.11% 74
2019
Q2
$3.13M Sell
43,112
-3,750
-8% -$295K 0.13% 75
2019
Q1
$3.78M Sell
46,862
-1,033
-2% -$84.5K 0.16% 68
2018
Q4
$4.42M Sell
47,895
-5,122
-10% -$450K 0.22% 60
2018
Q3
$5.01M Sell
53,017
-13,383
-20% -$1.27M 0.22% 62
2018
Q2
$6.15M Buy
66,400
+8,050
+14% +$786K 0.28% 63
2018
Q1
$5.52M Buy
58,350
+8,169
+16% +$897K 0.27% 64
2017
Q4
$4.85M Buy
50,181
+800
+2% +$75.4K 0.26% 59
2017
Q3
$4.39M Hold
49,381
0.25% 59
2017
Q2
$3.58M Sell
49,381
-5,637
-10% -$379K 0.22% 61
2017
Q1
$3.58M Sell
55,018
-3,050
-5% -$192K 0.22% 62
2016
Q4
$3.64M Buy
58,068
+1,428
+3% +$87.2K 0.25% 60
2016
Q3
$3.57M Sell
56,640
-4,851
-8% -$314K 0.25% 59
2016
Q2
$3.81M Sell
61,491
-1,222
-2% -$74.5K 0.27% 61
2016
Q1
$3.58M Buy
62,713
+139
+0.2% +$7.75K 0.26% 63
2015
Q4
$3.71M Sell
62,574
-1,460
-2% -$84.1K 0.27% 65
2015
Q3
$3.48M Buy
64,034
+5,686
+10% +$370K 0.27% 65
2015
Q2
$3.42M Hold
58,348
0.27% 64
2015
Q1
$3.42M Buy
58,348
+45,600
+358% +$2.75M 0.27% 64
2014
Q4
$834K Buy
12,748
+524
+4% +$33K 0.07% 108
2014
Q3
$706K Sell
12,224
-100
-0.8% -$5.55K 0.07% 108
2014
Q2
$696K Buy
12,324
+815
+7% +$42.8K 0.06% 104
2014
Q1
$592K Buy
11,509
+4,937
+75% +$250K 0.06% 107
2013
Q4
$347K Buy
6,572
+300
+5% +$14.7K 0.04% 140
2013
Q3
$281K Buy
6,272
+500
+9% +$22.2K 0.03% 145
2013
Q2
$239K Buy
+5,772
New +$252K 0.03% 153

Other funds holding ABBV

Douglass Winthrop Advisors's ABBV Position: Q2 2026 in Review

Douglass Winthrop Advisors increased its AbbVie (ABBV) stake by 16% in Q2 2026, buying an estimated $1.77M and bringing the position to 61,088 shares worth $15.4M. The position accounts for 0.27% of the portfolio, ranked #45.

Douglass Winthrop Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Douglass Winthrop Advisors held 61,088 shares of AbbVie worth $15.4M as of Q2 2026.
  • Douglass Winthrop Advisors bought 8,213 AbbVie shares in Q2 2026, an estimated $1.77M.
  • AbbVie made up 0.27% of Douglass Winthrop Advisors's portfolio in Q2 2026, its #45 holding.
  • Douglass Winthrop Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Douglass Winthrop Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.